The clinical results of Novartic CAR-T cell therapy are positive and are expected to result in a third adaptation.

Filtered lymphoma is the second most common type of non-Hodgkin's lymphoma (NHL) and is an inert lymphoma, accounting for about 22 percent of NHL cases.
although there are treatments to improve total survival, FL is considered an incurable malignant tumor, showing patterns of disease progression that are constantly recurring and remission.
in the lifetime of patients with relapsed FL, they may need to receive more than five different treatments, up to a maximum of 12.
addition, due to this pattern of relapse and remission of disease progression, patients who do not respond to treatment or who relapse quickly may have exhausted available treatment options.
Kymriah is the first FDA-approved CAR-T cell therapy to target CD19 antigens and the first car-T therapy to be approved for two distinct adaptations.
is a one-off treatment designed to boost a patient's immune system's ability to fight cancer.
Kymriah has been approved for the treatment of patients with R/R acute lymphoblastic leukemia (ALL) and adult patients with R/R diffuse large B-cell lymphoma (DLBCL).
resources: novartis announces Kymriah® meets primary endpoint at interim analysiss of the pivotal study in follicular lymphoma. Retrieved August 4, 2020, from.